Mesoblast Ltd Earnings
The next earnings date for Mesoblast Ltd has not yet been scheduled.
Analyst Estimates of Mesoblast Ltd Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Mesoblast Ltd Earnings: Historical
| 08/26/2026 | After Market | --- | --- |
| 05/29/2026 | --- | $0 | 100.00% |
| 11/26/2025 | --- | $-0.07 | 30.00% |
| 08/28/2025 | --- | $-0.04 | 90.00% |
| 05/30/2025 | --- | $0 | 100.00% |
| 02/26/2025 | --- | $-0.04 | 90.24% |
| 10/30/2024 | After Market | $-0.28 | 9.68% |
| 04/30/2024 | After Market | $0 | 100.00% |
| 02/28/2024 | After Market | $0 | 100.00% |
| 11/22/2023 | --- | $-0.13 | -6.81% |
More About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
“Mesoblast Ltd Earnings” Can Refer to the Mesoblast Ltd Earnings Date
Some people say “Mesoblast Ltd earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Mesoblast Ltd position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Mesoblast Ltd Stock on the Earnings Date
If you own Mesoblast Ltd stock (MESO) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Mesoblast Ltd might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Mesoblast Ltd shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Mesoblast Ltd Earnings
You can contact us any time if you would like to ask questions about Mesoblast Ltd earnings or anything else related to the stock market.